StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Ending balance related to prior years' product sales by Year

Ending balance related to prior years' product sales ($M) ($M)

Gilead Sciences Ending balance related to prior years' product sales: $365M in FY2025, up 5.8% from a year earlier.

Latest, FY2025
365
Period ended Dec 31, 2025
Change on a year earlier
+5.8%
345 in FY2024
History
13 years
Since FY2013
Sources
12
Documents cited below

Where the FY2025 figure comes from

“|| Activity related to sales prior to 2025 | 4,646 | (378) | (3,903) | 365”

Source: Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗

Reported in Form 10-K Critical Accounting Estimates.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Gilead Sciences Ending balance related to prior years' product sales ($M), annual FY2013–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/reb-end-prior

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.